| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
i
|
|
|
|
Introduction and overview
|
Jesús F. San-Miguel
|
S1-S3
|
|
|
|
Multiple myeloma: biology of the disease
Abstract: Multiple myeloma (MM) is a clonal B-cell malignancy characterized by the aberrant expansion of plasma cells within the bone marrow, as well as at extramedullary sites. Decades of scientific ...
|
Anuj Mahindra,
Teru Hideshima,
Kenneth C. Anderson
|
S5-S11
|
|
|
|
Lenalidomide mode of action: linking bench and clinical findings
Abstract: New effective strategies are required that specifically address the challenges of multiple myeloma (MM) treatment, namely, disease recurrence, immunosuppression, and treatment-related toxici...
|
Faith Davies,
Rachid Baz
|
S13-S19
|
|
|
|
Lenalidomide: an update on evidence from clinical trials
Abstract: Lenalidomide is a novel immunomodulatory agent with a unique dual mechanism of action: its tumoricidal effect leads to direct tumor cell death, and its immunomodulatory effect keeps the tumo...
|
Meletios-Athanassios Dimopoulos,
Evangelos Terpos
|
S21-S26
|
|
|
|
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies
Abstract: The introduction of thalidomide, lenalidomide, and bortezomib has changed the way that multiple myeloma (MM) is treated and has greatly improved survival outcomes. These novel agents are oft...
|
Gareth Morgan
|
S27-S32
|
|
|
|
Concluding remarks and future directions
|
Jesús F. San-Miguel
|
S33-S34
|
|
